Cargando…

Human metapneumovirus in paediatric patients

Acute respiratory tract infections (ARTIs) are a leading cause of morbidity and mortality in children worldwide, but the aetiology of many ARTIs is still unknown. In 2001, researchers in The Netherlands reported the discovery of a previously unidentified pathogen called human metapneumovirus (hMPV)....

Descripción completa

Detalles Bibliográficos
Autores principales: Principi, N., Bosis, S., Esposito, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128939/
https://www.ncbi.nlm.nih.gov/pubmed/16524405
http://dx.doi.org/10.1111/j.1469-0691.2005.01325.x
_version_ 1783516676524867584
author Principi, N.
Bosis, S.
Esposito, S.
author_facet Principi, N.
Bosis, S.
Esposito, S.
author_sort Principi, N.
collection PubMed
description Acute respiratory tract infections (ARTIs) are a leading cause of morbidity and mortality in children worldwide, but the aetiology of many ARTIs is still unknown. In 2001, researchers in The Netherlands reported the discovery of a previously unidentified pathogen called human metapneumovirus (hMPV). Since its initial description, hMPV has been associated with ARTI in Europe (Italy, France, Spain, the UK, Germany, Denmark, Finland and Norway), America (the USA, Canada, Argentina and Brazil), Asia (India, Japan, China and Singapore), Australia and South Africa in individuals of all ages. The incidence of infection varies from 1.5% to 25%, indicating that hMPV is a ubiquitous virus with a worldwide distribution. hMPV seems to play an important role as a cause of paediatric upper and lower respiratory tract infection, with similar, but not identical, epidemiological and clinical features to those of respiratory syncytial virus and influenza virus. Moreover, the socio‐economic impact of hMPV‐infected children on their families seems to be considerable, which suggests that, like influenza virus, hMPV infection may be a substantial public health problem for the community. It may be associated with significant morbidity and mortality in pre‐term infants and children with underlying clinical conditions, although more adequately controlled studies are needed to confirm its importance in such patients. Many fundamental questions concerning the pathogenesis of hMPV disease and the host's specific immune response remain to be answered. Further studies are also required to properly define hMPV diagnosis, treatment and prevention strategies.
format Online
Article
Text
id pubmed-7128939
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-71289392020-04-08 Human metapneumovirus in paediatric patients Principi, N. Bosis, S. Esposito, S. Clin Microbiol Infect Reviews Acute respiratory tract infections (ARTIs) are a leading cause of morbidity and mortality in children worldwide, but the aetiology of many ARTIs is still unknown. In 2001, researchers in The Netherlands reported the discovery of a previously unidentified pathogen called human metapneumovirus (hMPV). Since its initial description, hMPV has been associated with ARTI in Europe (Italy, France, Spain, the UK, Germany, Denmark, Finland and Norway), America (the USA, Canada, Argentina and Brazil), Asia (India, Japan, China and Singapore), Australia and South Africa in individuals of all ages. The incidence of infection varies from 1.5% to 25%, indicating that hMPV is a ubiquitous virus with a worldwide distribution. hMPV seems to play an important role as a cause of paediatric upper and lower respiratory tract infection, with similar, but not identical, epidemiological and clinical features to those of respiratory syncytial virus and influenza virus. Moreover, the socio‐economic impact of hMPV‐infected children on their families seems to be considerable, which suggests that, like influenza virus, hMPV infection may be a substantial public health problem for the community. It may be associated with significant morbidity and mortality in pre‐term infants and children with underlying clinical conditions, although more adequately controlled studies are needed to confirm its importance in such patients. Many fundamental questions concerning the pathogenesis of hMPV disease and the host's specific immune response remain to be answered. Further studies are also required to properly define hMPV diagnosis, treatment and prevention strategies. Blackwell Publishing Ltd 2006-01-23 2006-04 /pmc/articles/PMC7128939/ /pubmed/16524405 http://dx.doi.org/10.1111/j.1469-0691.2005.01325.x Text en This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
spellingShingle Reviews
Principi, N.
Bosis, S.
Esposito, S.
Human metapneumovirus in paediatric patients
title Human metapneumovirus in paediatric patients
title_full Human metapneumovirus in paediatric patients
title_fullStr Human metapneumovirus in paediatric patients
title_full_unstemmed Human metapneumovirus in paediatric patients
title_short Human metapneumovirus in paediatric patients
title_sort human metapneumovirus in paediatric patients
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128939/
https://www.ncbi.nlm.nih.gov/pubmed/16524405
http://dx.doi.org/10.1111/j.1469-0691.2005.01325.x
work_keys_str_mv AT principin humanmetapneumovirusinpaediatricpatients
AT bosiss humanmetapneumovirusinpaediatricpatients
AT espositos humanmetapneumovirusinpaediatricpatients